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Abstract
Background: Transarterial-chemo-embolization (TACE) is used for palliation of unresectable hepatocellular carcinoma
(HCC). We studied the tolerability of TACE in a cohort of patients with NASH and alcoholic cirrhosis related HCC.
Methods: Of 290 patients with HCC (July 2011 - December 2014), 84 underwent TACE. They were monitored
for post-TACE complications: postembolization fever (PEF), nausea and vomiting (NV), abdominal pain, infection,
acute hepatic decompensation (AHD) and acute kidney injury (AKI).
Results: 84 patients [90.5 % males, 89.2 % cirrhotics, 89.2 % nodular HCC, median age 63 (34–84) years]
underwent 111 TACE sessions. All were Child class A [69.4 % sessions (n = 77)] or B; ascites and portal vein
invasion was present in 18 (16.2 %) and 15 (13.6 %), respectively.
42 (38.2 %) TACE procedures resulted in complications [PEF 28 (25.2 %), NV 4 (3.6 %), abdominal pain 9 (8.1 %),
infection 7 (6.3 %), AHD 13 (11.7 %), AKI 3 (2.7 %)]. There were no immediate post-TACE deaths.
On univariate analysis elevated serum bilirubin (p = 0.046) and low serum albumin (p = 0.035) predicted PEF
while low serum albumin (p = 0.021) and low platelet counts (p = 0.041) predicted AHD. In the multivariate
model, factors with p < 0.200 on univariate analysis and factors derived from the previous literature were
considered covariates. Female gender (p = 0.029, OR = 1.412), ascites (p = 0.030, OR = 1.212), elevated serum
bilirubin (p = 0.007, OR = 4.357) and large tumour size (p = 0.036, OR = 3.603) were independent risk factors for
PEF. Tumour diameter >5 cm (p = 0.049, OR = 2.410) and elevated serum bilirubin (p = 0.036, OR = 1.517)
predicted AHD.
Conclusion: In NASH and alcoholic cirrhosis related HCC patients pre-procedure serum bilirubin, ascites,
tumour size and female gender predicted PEF post-TACE. Tumours larger 5 cm with elevated bilirubin
predicted AHD post-TACE.
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Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer worldwide and the third most common cause
of cancer related deaths. Eighty to ninety percent of pa-
tients with HCC have underlying cirrhosis [1]. Globally,
Hepatitis B (HBV) and Hepatitis C (HCV) are leading
causes of cirrhosis and HCC. HBV and HCV is uncom-
mon in Sri Lanka [2], and cases of cirrhosis are either al-
cohol related or non alcoholic steatohepatitis (NASH)
related [2]. Although published data are not available, clin-
ical impressions are that the incidence of cirrhosis and
HCC are rising in the country.
Though there are many advances made in the treatment
of HCC, the majority of tumours are diagnosed at an ad-
vance stage. As a result only a fraction of patients are eli-
gible for curative therapy such as liver transplantation and
resection [1]. Transarterial Chemo-embolization (TACE)
and Radio Frequency Ablation are considered two of the
most effective palliative treatments for inoperable HCC [3].
However, these patients need to be carefully selected to
prevent complication for the best patient outcomes as a
large majority of HCC patients have background cirrhosis.
Hepatocyte injury during the procedure, ischaemic tumour
necrosis and effects of chemotherapy can lead troublesome
complication. Recognized complications of TACE include
postembolization fever (PEF), nausea and vomiting (NV),
right hypochondrial pain and infections. Occasionally, pa-
tients may develop life threatening complications such as
acute hepatic decompensation (AHD) and acute kidney in-
jury (AKI) [4–6].
This study investigated the tolerance and factors affect-
ing tolerance to TACE in a cohort of patients with NASH
and alcohol related cirrhosis with HCC.
Methodology
A total of 290 consecutive individuals with alcoholic and
NASH related cirrhosis complicated by the development of
HCC, referred to the Hepato-Pancreatico-Biliary Unit of
the Colombo North Teaching Hospital, Ragama, Sri Lanka,
from July 2011 to December 2014 were included. 84/290
(29 %) patients underwent TACE; among these patients
111 TACE sessions were carried out.
Barcelona Clinic Liver Cancer (BCLC) tumour staging
was followed to select patients suitable for TACE [7]. TACE
was considered for unresectable intermediate-stage HCC
(BCLC stage B or Child-Pugh class A/B with large or
multifocal HCC, with no vascular invasion or extrahe-
patic tumour spread). However, selected patients with
vascular invasion were also offered TACE after consid-
ering the extent of thrombosis and the patients’ general
condition. Patients with complete portal vein throm-
bosis, high bleeding risk, total bilirubin level >3 mg/dl,
Child-Pugh class C and extensive tumour involvement
of more than 50 % of the liver were excluded.
Patients were given a single prophylactic dose of intra-
venous cefuroxime 750 mg and intravenous pantoprazole
40 mg one hour prior to the procedure. TACE procedure
was performed by creating an arterial access at the groin
under local anesthesia. The femoral artery was punctured
using the Seldinger method. After selective canulation of
the coeliac axis a 5 F/4 F Yashiro catheter was advanced
into the relevant hepatic artery. The feeding artery to the
tumour was selectively canulated using a micro catheter.
Once the catheter was entered to the feeding artery doxo-
rubicin 50 mg mixed with 10 ml Lipiodol was injected into
the tumour. After this, 4-5 ml gelatin sponge was injected
to occlude the feeding artery. The catheter was then with-
drawn and a pressure dressing is applied.
During the immediate post procedure period, patients
were monitored in the recovery area for any post pro-
cedure complications. Subsequently patients were trans-
ferred to the general ward. Regular antibiotics were only
added to patients with clear evidence of infection. Anti-
pyretics, analgesics and anti-emetics were not adminis-
tered prophylactically and were only given if patients
who developed PEF, pain or NV respectively. Patients
with NV were treated with IV Ondensetrone 8 mg and
PEF was treated with paracetamol. Duration and the fre-
quency of these medications were decided depending on
the response to treatment.
Patients were monitored for the development complica-
tions and the tolerability of the procedure clinically and
biochemically. In post procedure day 1 and 3 a biochemical
liver profile, prothrombin time, renal function tests and a
full blood count were performed. Development of any post
TACE complications such as PEF, NV, right hypochondrial
pain, AHD and AKI were documented. In the absence of
these complications, patients were discharged from hos-
pital on post procedure day 3. Thereafter, patients were
followed up at the out-patient clinic on post procedure day
7 with liver biochemistry, to detect delayed appearance of
complications.
PEF was defined as a body temperature greater than
38.0 °C that developed within 3 days of TACE without
evidence of infection [5]. ADH was define by the occur-
rence of clinical encephalopathy (West Haven grade 1 or
higher), development of clinically detectable ascites or
worsening of pre-existing ascites to clinically detectable
or tense ascites, increasing prothrombin time by more
than 3 s of the level prior to TACE, increase of serum
bilirubin level to twice the level prior to TACE (4). AKI
was defined as an abrupt increase in the serum creatin-
ine level to over 50 % of the baseline level [8].
Factors that predict the two most common complica-
tions, postembolization fever (PEF) and acute hepatic de-
compensation (AHD), were separately assessed in a
univariate analysis. Factors which had a p-value < 0.200 in
the univariate analysis and important factors reported in
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previous literature were then taken into a multivariate lo-
gistic regression model. In the statistical analysis cat-
egorical variables were described using percentages and
continuous variables were expressed using median and
range. Comparison of categorical variables was made using
chi square test and comparison of continuous variables was
made using the T test and Mann–Whitney U- test where
appropriate for an univariate analysis. Binary logistic regres-
sion was used for the multivariate analysis to find the most
significant risk factors. A p < 0.05 was considered sig-
nificant for all tests. Statistical analysis was performed
using SPSS 20.
Ethical approval for the study was granted by the Ethics
Review Committee of the Faculty of Medicine, University
of Kelaniya, Ragama, Sri Lanka.
Results and discussion
Results
Eighty four patients underwent 111 TACE sessions dur-
ing the study period. The median age of the population
was 63 years (range 34–84). 90.5 % (n = 76) of the
population were males. 89.2 % (n = 75) were cirrhotics.
All patients were in either Child class A or B. 69.4 %
(n = 77) of the TACE sessions were in Child class A pa-
tients. Majority (91.9 %) of the patients had a KF index
above 80. Ascites was present in the CT scans of
16.2 % (n = 18) patients. Majority of the HCC were of
the nodular type (n = 75; 89.2 %). Portal vein invasion
was present in 15 (13.6 %).
Forty two (38.2 %) TACE sessions resulted in post-
procedure complications. PEF was documented after 28
(25.2 %) sessions, NV after 4 (3.6 %), abdominal pain after
9 (8.1 %) and infection after 7 (6.3 %). AHD occurred fol-
lowing 13 (11.7 %) sessions and AKI after three (2.7 %).
There were no fatalities related to the TACE procedure.
There were no drop outs in this cohort. In absence of fa-
talities, all participants were reviewed day 7 post proced-
ure: those with complications as in-patients and those
discharged without complications as out-patients.
The univariate analysis indicated that a higher total
bilirubin level (p = 0.046) and lower serum albumin
level (p = 0.035) were possible risk factors for PEF
while a lower serum albumin (p = 0.021) and platelet
count (p = 0.041) were possible risk factors for AHD
(Table 1). In the multivariate model, factors with p < 0.200
in the univariate analysis and important factors in the
previous literature (4,8-11,14) were taken as covariates.
Female gender (p = 0.029, 0R = 1.412), presence of asci-
tes (p = 0.030, OR = 1.212), higher total bilirubin level
(p = 0.007, OR = 4.357) and larger tumour diameter (p =
0.036, OR = 3.603) were independent risk factors for devel-
opment of PEF following TACE. Tumour diameter >5 cm
(p = 0.049, OR = 2.410) and higher bilirubin levels (p =
0.036, OR = 1.517) were independent risk factors for
AHD (Table 2).
Table 1 Univariate analysis of factors effecting development of post embolization fever (PEF) and acute hepatic decompensation (AHD)
Variables Patients with fever (n = 28) Patients without
fever (n = 83)
p-value Patients with liver





Age (years) 64 (37–84) 63 (34–78) 0.916 64 (37–84) 62 (34–76) 0.924
Gender (Males) 23 (84 %) 77 (93.2 %) 0.188 10 (83.3 %) 89 (91.2 %) 0.363
Diabetics 17 (55.9 %) 46 (55.6 %) 0.995 07 (55.6 %) 57 (58.3 %) 0.858
Body mass index (kg/m2) 25.03 23.88 0.124 24.18 24.33 0.842
KF index (<80 %) 03 (10 %) 03 (3.8 %) 0.198 02 (15.3 %) 08 (8.1 %) 0.199
Child Class B 09 (33.3 %) 14 (16.7 %) 0.252 04 (35.4 %) 28 (29.4 %) 0.743
Presence of ascites in computed tomogram 05 (17.9 %) 07 (8.1 %) 0.149 02 (15.3 %) 08 (8.1 %) 0.493
INR 1.23 1.15 0.546 1.21 1.16 0.451
Platelet count (/ml) 156×103 171×103 0.241 128×103 177×103 0.021
AST (U/L) 67.38 58.2 0.274 66.8 59.7 0.512
ALT(U/L) 46.1 48.6 0.703 46 48.3 0.782
Total Bilirubin (mg/dl) 1.39 0.71 0.046 1.35 0.87 0.094
Albumin (mg/dl) 3.30 3.51 0.035 3.14 3.49 0.041
Serum Creatinine (mg/dl) 1.11 0.89 0.321 1.07 0.92 0.235
Total tumour diameter (cm) 7.93 6.14 0.102 8.17 6.48 0.123
Type of HCC (diffuse %) 03 (1079 %) 03 (4 %) 0.311 02 (16.6 %) 72 (7.4 %) 0.292
Presence of Portal vein invasion 04 (16.2 %) 09 (11.3 %) 0.167 02 (16.6 %) 11 (11.9 %) 0.786
KF index-Karnofsky performance index, AST- aspartate amino transferase, ALT- Alanine amino transferase, INR- international normalized ratio
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Discussion
Our cohort of patients is unique in that none of them had
cirrhosis secondary to infective hepatitis. In these patients
with NASH and alcoholic cirrhosis related HCC, 38 % of
TACE procedures resulted in complications; PEF (25.2 %)
and AHD (11.7 %) were the commonest. There were no
immediate post-TACE deaths. Female gender, tumour size
over 5 cm, presence of ascites prior to the procedure and
a high bilirubin level were predictors of post-TACE PEF.
Lager tumour diameter and a high bilirubin level were
predictors of AHD. The incidence of overall complications
previously reported following TACE is about 30-70 % [6].
The commonest complication reported is PEF, occurring
in 20-70 % in different settings [5, 9]. AHD has been pre-
viously reported in 5-20 % [4, 10, 11], infective complica-
tions, which include liver abscess and positive blood
culture, in around 5 % [12], and upper gastrointestinal
bleeding in 5-10 % of the patients following TACE [6].
The mechanism of PEF been extensively discussed.
Most available evidence suggests that it is a result of col-
lateral damage to normal liver tissue rather than tumour
necrosis itself [13, 14], and hence does not influence sur-
vival. In a multivariate analysis, lipiodol dose and the
post embolization AST level were predictors of PEF [9].
In another study, tumour size, AST level and lipiodol
dose predicted PEF [6]. In our patients a standard dose
of lipiodol was used in all cases. In our cohort we se-
lected patients with a serum bilirubin less than 3 mg/dl.
Even among them, a relatively higher bilirubin level and
the presence of even mild ascites on abdominal CT inde-
pendently predicted PEF. We noted an association between
PEF and tumours larger than 5 cm. Data from previous
studies does not support this finding [5]. We cannot ex-
plain why being female seemed to predict PEF. Though
PEF is self-limiting and has no impact on post procedure
survival, the complication is important for pre-procedure
patient counseling.
AHD and liver failure are dreadful complications that lead
to significant morbidity and mortality. Higher bilirubin levels
indicate poor background liver function and we found that a
large tumour diameter and a high bilirubin level predicted
of AHD. Similar findings have been reported by others [4,
10], and TACE in patients with tumours larger than 5 cm
has been associated with post procedure liver failure. In our
cohort there were no deaths due to AHD and liver failure
and all patients were successfully managed medically. How-
ever, hospital stay was prolonged up to one to two week.
Though a higher serum bilirubin and tumour size should
not be contraindications, such patients should be warned,
and prior anticipation and precautions may reduce AHD
and its progression to liver failure.
Minority of patients developed complications such as
NV, abdominal pain, infection and AKI. These were
transient and responded well to standard treatment.
NV was managed with anti-emetics. Abdominal pain
responded well to simple analgesics such as paracetamol,
not exceeding total daily dose of 2 g per day. This dose was
well tolerated by the patients. Infections were treated with








Odds ratio (95 % confidence interval)
Genderb 0.029 1.142 -
(1.328-3.342)
KF index (<80 %) 0.970 0.423 0.808 1.018
Child classa - 0.571 0.449
Presence of ascites 0.030 1.212 0.850 0.712
(1.023-2.231)
Platelet counta - 0.324 0.325
ASTb 0.542 0.243 -
Total bilirubin 0.007 4.357 0.036 1.517
(2.443-6.219) (1.112-4.536)
Albumin 0.126 0.564 0.060 0.965
Tumour diameter (>5 cm) 0.036 3.603 0.049 2.410
(1.318-5.382) (1.392-5.315)
Presence of portal vein invasiona - 0.523 0.376
Type of tumour 0.437 0.785 0.134 0.879
KF index-Karnofsky performance index, AST- aspartate amino transferase
a- factors not included in multivariate analysis for PEF
b- factors not included in multivariate analysis for AHD
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intravenous ceftriaxone 1 g twice daily for three 3 to five
days. There were no cases of confirmed spontaneous bac-
terial peritonitis. AKI was transient and responded well to
rehydration. None required treatment escalation to include
volumes expansion, vasoconstrictors or renal replacement
therapy.
We did not encounter upper gastro intestinal bleeding
post-TACE. In previous literature this is reported to occur
in about 5-10 % [6]. As a routine practice we eradicated
varices in all our patients before undertaking TACE and
all patients were on low dose proton pump inhibitors be-
fore and after the procedure, which may have played a role
in this this complication not developing in our patients.
Relative short term follow up period of this study is a
limitation. Therefore, observation for the development
of delayed complications such as hepatic abscess was
not possible in this study.
Careful selection of patients for TACE in the setting of
HCC, will likely reduce anticipated complications of this
procedure. The predicator of such complications, from
the present study and as well as from previously pub-
lished studies, should guide clinicians for early detection
and treatment of post-TACE complications.
Conclusion
In this cohort of HCC patients with NASH and alcohol re-
lated cirrhosis, 38 % of TACE procedures resulted in com-
plications, of which PEF and AHD were the commonest.
Female gender, pre-procedure serum bilirubin, ascites, and
tumour size predicted PEF post-TACE. Tumours larger
than 5 cm and elevated serum bilirubin predicted the devel-
opment of AHD post-TACE. In this cohort there were no
fatalities related to TACE.
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